A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
Study sponsor: Viking Therapeutics, Inc. · VKTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-15Actual
Enrollment · participants248Actual
Source updated2024-06-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.